

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.

樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

VOLUNTARY ANNOUNCEMENT

INCREASE IN SHAREHOLDING BY THE CONTROLLING SHAREHOLDER

This announcement is made by the board (the **“Board”**) of directors (the **“Directors”**, each a **“Director”**) of Lepu Biopharma Co., Ltd. (the **“Company”**) on a voluntary basis.

The Board has been informed by Dr. Pu Zhongjie (**“Dr. Pu”**), the chairman of the Board and executive Director, and a controlling shareholder of the Company, that he has purchased an aggregate of 1,050,000 H shares of the Company (the **“H Shares”**) in the open market via Shanghai-Hong Kong Stock Connect on October 27, 2026 at an average price of approximately RMB3.04 (equivalent to HKD3.55) per H Share with his own funds, representing approximately 0.06% of the total number of issued shares of the Company (the **“Shares”**) as at the date of this announcement.

Dr. Pu informed the Board that his increase in shareholding in the Company demonstrates his sustained confidence in the business prospects, growth potential and long-term investment value of the Company. In particular, Dr. Pu believes that the Company continues to be well-positioned to benefit from its innovation-driven approach in its R&D and commercialization efforts, supported by promising clinical data and the vast potential of its products pipeline.

Immediately following the increase in shareholding and as at the date of this announcement, Dr. Pu holds (i) directly 1,050,000 H Shares and (ii) indirectly holds 433,239,436 H Shares and 225,352,113 H Shares through Ningbo Houde Yimin Information Technology Co., Ltd. (寧波厚德義民信息科技有限公司, a company indirectly wholly-owned by Dr. Pu) and Lepu Medical Technology (Beijing) Co., Ltd. (樂普(北京)醫療器械股份有限公司, a company of whom Dr. Pu is the actual controller), respectively, representing approximately 36.6% of the total number of issued Shares. Based on the information that is publicly available to the Company and to the knowledge of the Directors, immediately following the increase in shareholding and as at the date of this announcement, the Company continues to comply with the minimum public float requirement under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC, October 27, 2026

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman) and Dr. Sui Ziyue (chief executive officer) as executive Directors; Ms. Pu Jue and Ms. Qin Yiran as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.